Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
07 2021
Historique:
revised: 17 03 2021
received: 14 10 2020
accepted: 23 03 2021
entrez: 30 6 2021
pubmed: 1 7 2021
medline: 30 10 2021
Statut: ppublish

Résumé

In recent years, many countries have adopted evidence-based budgeting (EBB) to encourage the best use of limited and decreasing HIV resources. The lack of data and evidence for hard to reach, marginalized and vulnerable populations could cause EBB to further disadvantage those who are already underserved and who carry a disproportionate HIV burden (USDB). We outline the critical data required to use EBB to support USDB people in the context of the generalized epidemics of sub-Saharan Africa (SSA). To be considered in an EBB cycle, an intervention needs at a minimum to have an estimate of a) the average cost, typically per recipient of the intervention; b) the effectiveness of the intervention and c) the size of the intervention target population. The methods commonly used for general populations are not sufficient for generating valid estimates for USDB populations. USDB populations may require additional resources to learn about, access, and/or successfully participate in an intervention, increasing the cost per recipient. USDB populations may experience different health outcomes and/or other benefits than in general populations, influencing the effectiveness of the interventions. Finally, USDB population size estimation is critical for accurate programming but is difficult to obtain with almost no national estimates for countries in SSA. We explain these limitations and make recommendations for addressing them. EBB is a strong tool to achieve efficient allocation of resources, but in SSA the evidence necessary for USDB populations may be lacking. Rather than excluding USDB populations from the budgeting process, more should be invested in understanding the needs of these populations.

Identifiants

pubmed: 34189873
doi: 10.1002/jia2.25707
pmc: PMC8242975
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25707

Subventions

Organisme : NIMH NIH HHS
ID : K01 MH119923
Pays : United States

Informations de copyright

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

JMIR Public Health Surveill. 2017 Oct 20;3(4):e72
pubmed: 29054832
Lancet. 2018 May 5;391(10132):1799-1829
pubmed: 29678342
Epidemiology. 2018 Nov;29(6):795-803
pubmed: 30119057
Open AIDS J. 2016 Apr 08;10:34-48
pubmed: 27347270
Infect Dis Poverty. 2019 Jul 2;8(1):58
pubmed: 31262365
PLoS One. 2020 Feb 26;15(2):e0228634
pubmed: 32101551
PLoS One. 2016 May 10;11(5):e0155150
pubmed: 27163256
AIDS. 2020 May 1;34(6):883-891
pubmed: 32004205
Curr Opin HIV AIDS. 2014 Mar;9(2):101-6
pubmed: 24464090
PLoS One. 2019 Feb 26;14(2):e0210497
pubmed: 30807573
Curr Opin HIV AIDS. 2014 Mar;9(2):115-25
pubmed: 24356328
Curr Opin HIV AIDS. 2019 Sep;14(5):337-353
pubmed: 31368909
Curr Opin HIV AIDS. 2014 Mar;9(2):107-14
pubmed: 24393694
BMC Med Inform Decis Mak. 2018 Jan 5;18(1):2
pubmed: 29304788
BMC Public Health. 2009 Nov 18;9 Suppl 1:S4
pubmed: 19922688
AIDS. 2019 Dec 15;33 Suppl 3:S213-S226
pubmed: 31490781
Lancet. 2015 Jan 3;385(9962):72-87
pubmed: 25059942
J Int AIDS Soc. 2017 Mar 17;20(1):21386
pubmed: 28364567
J Int AIDS Soc. 2021 Jan;24(1):e25650
pubmed: 33533115
AIDS. 2014 Mar 27;28(6):891-9
pubmed: 24401648
AIDS Behav. 2015 Feb;19 Suppl 1:S3-15
pubmed: 25582921
JMIR Public Health Surveill. 2018 Aug 07;4(3):e10188
pubmed: 30087089
J Int AIDS Soc. 2021 Jul;24 Suppl 3:e25707
pubmed: 34189873
Health Policy. 2019 Jan;123(1):104-108
pubmed: 30497785
J Int AIDS Soc. 2019 Jul;22(7):e25325
pubmed: 31287620
BMJ Open. 2016 Mar 06;6(3):e009656
pubmed: 26948960
South Afr J HIV Med. 2016 Mar 15;17(1):455
pubmed: 29568613

Auteurs

Lawrence C Long (LC)

Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa.

Sydney Rosen (S)

Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa.

Brooke Nichols (B)

Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa.

Bruce A Larson (BA)

Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa.

Nhlanhla Ndlovu (N)

Centre for Economic Governance and Accountability in Africa (CEGAA), Pietermaritzburg, South Africa.

Gesine Meyer-Rath (G)

Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Health Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH